Uveitic glaucoma presents a treatment challenge because of the need to control two conditions. Furthermore, side effects of conventional treatments for uveitis—corticosteroids and systemic immunomodulatory agents—limit their use.
Technology makes great tool, requires extra vigilance with co-existing disease
Physicians also can focus on treating inflammation and IOP in patients
Though anterior uveitis is associated with myriad conditions, a relatively short list of disorders accounts for the vast majority of cases.
Inhibition plays role in autoimmune-based inflammation; has unique mechanism of action
Improvement in visual acuity, central retinal thickness, vitreous haze reported at 6 months
FA implant effective in lowering recurrence rates through available 6, 12 months of follow-up
Quiescence, steroid-free quiescence achieved in VISUAL III trial
One biologic response modifier has indication for uveitis; several in development to gain FDA approval
Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder